The 4th New Bavi trial listed in today's PR, the Ph.2 Bavi+Chemo/Triple-BC, with Dr. David Page's (protege of Mem.Sloan's Dr. Jedd Wolchok) involvement at the Providence CC in Oregon, has EVOLVED since the 10-15-15 ASM Presentation (which said, “combination under review”) – obviously with further input from Mem.Sloan-Kettering...
Phase I => Phase II Her2- => Triple- - - - - - - - - - - - - 10-15-15/ASM: Phase1 Early Stage Her2- Breast Cancer http://tinyurl.com/o6z4bm4 => 1-11-16 PR: Phase2, Bavi+Chemo, Early Stage TNBC(Triple-) Breast Cancer http://tinyurl.com/zhdy37a
= = = = = = = = = From today's (1-11-16) PR - PLANNED TRIALS... #4. Phase II Trial in Early Stage TNBC in Combination with Chemotherapy Peregrine is planning to initiate a Phase II trial of bavituximab in combination with neoadjuvant chemotherapy in early stage TNBC. The primary endpoint of this study is to determine the pathologic complete response rate (pCR), an accepted surrogate endpoint in early stage TNBC. The concept for this neoadjuvant setting trial, which will be conducted at a few select U.S. sites, originated from Peregrine's ongoing collaboration with Memorial Sloan Kettering Cancer Center (MSKCC). The company has filed a study protocol to its existing bavituximab IND application in the U.S. and is currently working to open clinical trial sites, including one that will be led by David B. Page (worked prev. with Dr. Jedd Wolchok at Mem.Sloan), M.D., at the Providence Cancer Center in Oregon. http://tinyurl.com/zhdy37a & http://tinyurl.com/h2g4nqd
Market Data 
Markets 
AI
